Detection of C3 and C5 on Monoeytes by the Direct Immunofluorescent Antibody Technique. Anti-C3
F(ab')2 and anti-C5 F(ab')2 were conjugated with fluorescein isothioeyanate (FITC) for use in immunofluorescence microscopic studies as described previously (25) . Immunofluorescence staining of cells was accomplished by treating adherent monocytes on glass cove/slips with fluorescent antibody fragments at a concentration of 0.6 mg/ml protein in medium for 30 rain at 37°C. Cultures were then washed three times with medium, and examined as a wet mount preparation using a Zeiss photoscope III (Carl Zeiss, Inc., New York) equipped for epifluorescent illumination with a BG 450-490 excitation filter, FT510 beam splitter, and BP 520 barrier filter.
Assay for Factor Bb-induced Monocyte Spreading. Spreading of human monocytes was assayed as described previously (11) by adding 0.3 ml of 3/zg factor Bb/ml to 3-d human monocyte cultures on glass cove/slips. Monocytes treated with factor Bb for 3 h were spread two to three times wider and up to six to eight times longer than control untreated monocytes (11) . Measurements of cell surface area and circumference were performed using planimetry and phase-contrast photomicrographs of monocytes at a final magnification of × 2,500. Adherent human monocytes were found to have a cell-surface area of 400 ± 100 m# a (SD) and a circumference of 56 ± 10 rn# (SD); in contrast, monocytes treated with factor Bb for 3 h were found to have a cell surface area of 2,100 + 400 m/z 2 (SD) and a circumference of 230 ± 80 m# (SD). For routine analysis, spreading was assessed microscopically on viable cultures at × 400 magnification using an inverted microscope fitted with a 0.5-mm ocular grid. A monocyte was considered to be spread if at least one of its dimensions was more than twice that of "unspread" monocytes in control cultures. The percentage of spread monocytes was determined by counting two to three microscopic fields (containing 200-300 cells) for each cove/slip culture. The mean percentage ± standard deviation was calculated from the results of duplicate or triplicate samples.
Assays for Inhibition of Monocyte Spreading.
Inhibition of monocyte spreading by Fab' or Fab antibody fragments was assayed by adding 0.3 ml of dilutions of Fab' or Fab in medium to 3-d cultures of glass-adherent monocytes for 15 min at 37°C. The responsiveness of treated monocytes was tested by adding I0 #l of a stock solution of 90 #g factor Bb/ml, and by counting the number of spread and unspread cells after 3 h, as described above.
Radiolabeling of C5 in Monoeyte Extracts with [t4C]-and [3HJLag.ine. Biosynthesis of C5 by
monocytes was investigated by preparing monocytes from 1-2 liters of fresh human blood by a modification of the four-step procedure described above. Briefly, monocytes were prepared by centrifugation (2,000 rpm for 20 rain) on 80 ml of Ficoll-Hypaque 1.09 g/ml and then 1.077 g/ml in 250-ml centrifuge bottles using an International PR-2 centrifuge (International Equipment C,o., Needham Heights, Mass.). The remaining preparative steps were performed as described previously (11) . Conditions for radiolabeling with [SH]-or [14C]leucine (120 or 325 mCi/mM, respectively; New England Nuclear, Boston, Mass.) are described in the text. After labeling, adherent monocytes were washed three times with medium and twice with PBS, and then extracted with 100-200 ml of 1% Triton X-100 in 2 mM sodium carbonate buffer, pH 7.5, containing 1.0 mM phenylmethylsulfonylflouride. Extracts were centrifuged 12,000 g for 30 rain to remove cellular debris, and concentrated by uhrafihration on Amicon PM30 membranes (Amicon Corp., Lexington, Mass.) to a final volume of I-2 ml. Samples were analyzed for radiolabeled C5 by adding goat anti-C5 Ig and 10% NHS (as a carrier antigen); immunoprecipitates were collected by centrifugation, washed, and dissociated in ABS, pH 3.0, containing I% SDS; solubilized precipitates were analyzed by SDS-PAGE (24) . Radioactivity was determined by slicing the acrylamide gels, solubilizing them in Protosol (New England Nuclear), and by counting in a Beckman LS 230 liquid scintillation counter (Beckman Instruments, Inc., Fullerton, Calif.). In other experiments, moncytes were labeled with [i*C]leucine and C5 was precipitated with goat anti-C5 Ig by double immunodiffusion in 2% agarose containing 1% Triton X-100. Nonspeeifically trapped radioactivity was removed by washing twice a day for 5 d with veronal-buffered saline containing 1% Triton; then for 1 d with PBS; and finally for 1 d with distilled water. Specifically bound radioactivity was determined by autoradiography for 20 d with X-ray film (Eastman Kodak Co., Rochester, N. Y.).
Results
Experiments were performed to investigate whether C3 or C5 were expressed on the monocyte surface, and whether these proteins play a role in the spreading reaction induced by Bb.
Demonstration of C3 and C5 Antigens on Monocytes by the Direct Fluorescent Antibody Technique. The expression of C3 and C5 on monocytes was investigated by the direct immunofluorescent antibody technique employing monospecific FITC-conjugated goat anti-C3 and anti-C5 F(ab')2 antibody fragments. Positive immunofluorescence staining was observed with FITC-conjugated anti-C5 F(ab')2 on 6 + 7% of freshly prepared monocytes and on 70 + 6% of monocytes incubated for 3 d in vitro in serumfree medium. The fluorescence micrographs presented in Fig. 1 show patching and capping of cell-surface determinants, which were stained by anti-C5 F(ab')2 at 37°C.
In parallel studies, the expression of C3 on monocytes was investigated and weak fluorescence staining was observed with FITC-conjugated anti-C3 F(ab')2 on 6 + 5% of freshly prepared monocytes. Fig. 2 indicate that anti-C5 Ig precipitates a tritiumlabeled monocyte protein that has the same mobility in SDS-PAGE as purified C5 run in a replicate gel. In other experiments, the kinetics of C5 synthesis was investigated by incubating monocytes with [14C]leucine, extracting cells with Triton X-100, Fie. 1. Positive immunofluorescence staining at 37°C of human peripheral blood monocytes by FITC-conjugated goat anti-C5 F(ab')2: monocyte cultures maintained for 3 d in vitro in serum-free medium before staining; original magnification X 660.
FIG. 2. Incorporation of [nH]
leucine by human peripheral blood monocytes into immunoprecipitable C5-antigen, which was extracted from cells with Triton X-100 and detected on SDS-PAGE by scintillation counting of gel slices: the upper panel is purified C5; the lower panel is immunoprecipitable monoeyte C5 run on a replicate gel.
and precipitating radiolabeled C5 antigen by double immunodiffusion in agarose with goat anti-C5 Ig and 10% NHS as a carrier antigen. After washing to remove free radiolabeled proteins, the immunoprecipitates were analyzed for precipitated 14C-labeled C5 antigen by autoradiography with X-ray film. Radiolabeled C5 antigen was detected in five out of five immunoprecipitation tests performed with extracts of monocytes at days 4, 7, and 11 of in vitro serum-free culture; however, no radiolabeled C5 antigen was detected (0/9 tests) on days 1, 2, or 3. In other experiments, an attempt was made to promote C5 synthesis by monocytes on days 1-3 of culture by adding 2-5% autologous serum to the culture media; however, no effect was noted. C5 antigen was detected in extracts of monocytes maintained in serum-containing cultures only after day 3. It is significant that monocytes incubated under these conditions do not acquire responsiveness to Bb-induced spreading until after day 3 (11).
Inhibition of Bb-induced MonocyUs Spreading by Anti-C5 Fab and Fab' Antibody
Fragments. The possible role of C3 and C5 in the factor Bb-induced monocyte spreading reaction was investigated by treating monocytes with Fab antibody fragments directed toward these proteins. Monocytes were treated at 37°C for 30 min with dilutions of anti-C3 or anti-C5 Fab and Fab'; Bb was then added to the assays and the percentage of cells spread was determined 3 h later. The results presented in Fig. 3 indicate that anti-C5 Fab or Fab' inhibited monocyte spreading by up to 95%. Less than 10% of monocytes treated with anti-C5 Fab' were observed to be spread compared wth 60-90% spread in control cultures receiving Bb alone. Anti-C3 Fab or Fab' did not inhibit monocyte spreading induced by Bb (Fig. 3) . We reasoned that anti-C5 Fab' might exert its inhibitory effect on monocyte spreading by binding to cell surface C5 antigen. To test whether such binding of anti-C5 Fab' was a sufficient condition for the expression of its inhibitory activity, monocytes were treated with anti-C5 Fab', washed, and then Bb was added. As a control, monocytes were treated in a similar manner with anti-C3 Fab'. The results presented in Table I indicate that a brief exposure to anti-C5 Fab' was sufficient to inhibit a significant percentage of monocytes from spreading when they were treated with factor Bb: spreading induced by Bb was inhibited by 53% when monocytes were pretreated for 20 rain at 20°C. In contrast, pretreatment with anti-C3 Fab' was without effect (Table I) . (Anti-C5 Fab' did not cause cells that were already spread to become unspread). Experiments were next conducted to quantitatively compare the inhibitory activity of anti-C5 Fab' in monocyte spreading assays with the inhibitory activity in complement hemolytic assays. (Anti-C5 Fab' used in these experiments was the same as that used in the experiments presented in Fig. 3 and Table I .) It was found that anti-C5 Fab' (a) inhibited by 50% the monocyte spreading reaction of 1-2 X 105 cells at a dilution of The specificity of the anti-C5 Fab' inhibitory effect on monocyte spreading was investigated by absorbing anti-C5 Fab' with highly purified C5. For these studies, C5 was purified by conventional techniques (12), and then subjected to further purification by electrophoresis on the elution from alkaline polyacrylamide gels (23). Anti-C5 Fab was titered to determine the lowest dilution giving 95-100% inhibition of monocyte spreading, this dilution was then absorbed with 1-10 #g of highly purified C5 for 15 rain at 22°C. The results presented in Table II (Table II) .
We reasoned that if factor Bb exerts its effects on monocytes by interacting with C5 on the cell-surface, the addition of relatively large amounts of C5 to the reaction Table  III confirm this hypothesis and indicate that 25-50 #g of C5 inhibit the monocyte spreading reaction induced by 1 #g of factor Bb. In data not presented here, control experiments were performed in which up to 200/~g of human IgG (Cohn fraction II), human albumin, or ovalbumin were added to the monocyte spreading assay. The addition of these proteins to the assay did not inhibit monocyte spreading induced by factor Bb. The addition of C5 to monocytes that had already been induced by Bb to become spread did not cause these cells to become unspread.
Discussion
The spreading of mononuclear phagocytes has been viewed as one in vitro manifestation of a state of increased macrophage activity in vivo. Recently, it has been shown that the central serine esterase of the alternative pathway of complement activation, Bb, induces murine macrophages (10) and human monocytes (11) to become spread on a glass substrata. It has also been established that to induce the spreading reaction, the catalytic site of the Bb enzyme must be structurally intact since treatment of Bb with heat (56°C for 30 min.) or diisopropyl fluorophosphate (10 -~ M) destroyed both enzymatic and spreading activities (9) (10) (11) (12) .
Native factor B is a single chain polypeptide of 93,000 mol wt, which enters into an Mg÷+-dependent complex with G3b (C3b,B) and is cleaved by factor D, yielding fragments of 60,000 and 33,000 mol wt (14) , termed Bb and Ba, respectively (9, 12 14) . Binding and cleavage of B initiate formation of the C3b,Bb complex, which is the G3/G5 convertase of the APC. The serine esterase activity of this complex is associated with Bb (9, (12) (13) (14) (15) , whereas the localization of the complex on biological membranes is a property of the C3b molecule, which transiently expresses an active thioester group that can form covalent bonds with molecules in the surface of particles that activate the APC (26) (27) (28) (29) (30) (31) (32) . Cleavage of C3 by cell-bound G3b,Bb leads to the deposition of additional G3b molecules on the surface that are required to express C5 convertase activity (33) . It has recently become apparent that cell-bound C3b or fluidphase C3b (34) binds to C5 with a low affinity; and that such cell-bound (33) or fluid-phase-complexed (34) G5 is susceptible to cleavage by the APC C5 convertase. In molecular terms, it is probable that expression of C5 convertase activity involves binding of C5 to multiple C3b molecules where one or more of the C3b molecules also contains bound Bb enzyme. Bb released from the C3b,Bb complex by decay dissociation fails to bind to C3b, causing it to lose its potential as a significant C3 or C5 convertase (9) . However, free Bb retains esterolytic activity on synthetic substrates (9, (12) (13) (14) (15) and a limited ability to cleave plasminogen (35) and prothrombin (36) . It is possible that under appropriate conditions, free Bb may also cleave C3 and C5 or that Bb may to a limited extent be able to reform a C3b,Bb complex on the cell surface.
The restricted substrate specificity of factor Bb in the complement system raised a question about whether either of the natural substrates of Bb might serve as a monocyte surface substrate for Bb in inducing the monocyte spreading reaction. In preparation for the present study, experiments were conducted to define the optimum conditions for stimulation of monocyte spreading by factor Bb, and the results of these experiments have been published previously (11) . Studies have also been initiated to investigate whether Bb stimulates changes in monocyte "marker-enzyme" systems and it has been found that Bb stimulates (a) a chemilluminescence response in 3-d serum-free cultures of human peripheral blood monocytes and (b) plasminogen activator secretion (J. S. Sundsmo, unpublished data). Significantly, it was found that human peripheral blood monocytes require 3 d incubation in vitro to acquire responsiveness to factor Bb-induced spreading (11) . This finding caused us to investigate in the present study whether the surface expression of C3 or C5 on monocytes changed during in vitro culture in serum-free medium and it was found that the percentage of monocytes staining positively for C3 or C5 was 6 + 7% at the initiation of in vitro culture, and that anti-C5 staining increased to 70 + 6% after 3 d incubation in serum-free medium, whereas C3 staining remained constant (Fig. 1) . Biosynthesis of C5 by monocytes was investigated using [x4C]-and [3H]leueine, immunoprecipitation techniques, and SDS-PAGE to evaluate C5 antigens in Triton X-100 extracts of monocytes. It was found that monocytes incorporate radiolabeled leucine into a protein with an apparent mol wt of 180,000, which is antigenically similar to serum C5 (Fig. 2) ; and that the radiolabeled C5 antigen was only detected in cell extracts after 3 d of in vitro incubation. It is perhaps significant that C5 may be acquired by human monocytes during a time in which monocyte maturation into macrophages has been recognized to take place in vitro (37) (38) (39) . The finding of biosynthetically radiolabeled C5 confirms and extends the observations of Stecher and Thorbecke (40), Levy et al. (41) , and Ooi and Colten (42, 43) , and Ooi et al. (44) , who have reported that murine macrophages synthesize C5.
Involvement of cell-surface C3 or C5 in the monocyte spreading reaction induced by factor Bb was investigated in the present study by testing for the ability of anti-C3 and anti-C5 Fab' fragments to inhibit the spreading reaction induced by factor Bb. Anti-C5 Fab' (but not anti-C3 Fab') was found to block by up to 100% the spreading induced by factor Bb in a serum-free system (Fig. 3) . Inhibition by anti-C5 Fab' was found to be exerted in a dose-dependent fashion (Fig. 3 ) and the inhibitory effect was exerted when monocytes were treated with anti-C5 Fab' and washed before the addition of factor Bb ( Table I ), suggesting that anti-C5 Fab' exerts its inhibitory effect on the monocyte spreading reaction by binding to monocytes rather than by interfering with some presumptive fluid-phase reaction involving factor Bb. The antigenic specificity of this inhibitory effect was established by absorbing anti-C5 Fab' with PAGE-purified C5 and this treatment caused the inhibitory activity of anti-C5 Fab' to be quantitatively decreased. We reasoned that if factor Bb exerts its effect on monocytes by interacting with cell-surface C5, then the addition of purified C5 to the reaction mixture might competitively inhibit the action of Bb on monocyte surface C5. This hypothesis was confirmed when it was found that fluid-phase C5 inhibited the action of Bb if it was added in 20-100-fold molar excess of the amount of factor Bb needed to induce the monocyte spreading reaction (Table III) . These results suggest a previously unrecognized property of Bb, namely, that purified Bb interacts with C5 on the monocyte surface or in fluid phase in the absence of C3b.
The results presented here are analogous to those we have reported previously (45) in a study designed to investigate expression of complement proteins on lymphocytes and the possible functional role of C5 in lymphocyte activation. In that study, human peripheral blood lymphocytes were found to synthesize C5, which had an apparent mol wt of 180,000 on SDS-PAGE; lymphocytes stimulated with phytohemagglutinin incorporated [x4C]leueine into C5, C6, C7, and C8 antigens as detected by immunoprecipitation in two-directional immunodiffusion and autoradiography (45); and anti-C5 Fab' antibody fragments inhibited lymphocyte stimulation by phytohemagglutinin-mitogen or allogeneic mixed lymphocyte culture as determined by inhibition of [SH]thymidine incorporation (46) .
It is established that many agents induce monocyte spreading in vitro (7). What is unique about factor Bb of the complement system is that mononuclear phagocytes have been reported to synthesize factor B (47-49), factor D (48, 50), C3 (40, (51) (52) (53) and C3b inactivator (50, 54) , giving these cells the potential to activate complement through the alternative pathway and to regulate complement activation. In addition, elastase, which is associated with mononuclear phagocytes (55, 56) , has been shown to cleave C3 generating a "C3b-like" fragment, which is functionally active in consuming factor B (56); and, plasmin, which is also capable of cleaving factor B (14) and C3 (57) , has been shown to be formed following secretion ofplasminogen activator from "activated" macrophages (58) (59) (60) . Leukocytes and lymphoblastoid cells activate complement (25, (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) ; cellular receptors have been identified that bind complement activation fragments (71) , and the Bb complement activation fragment has been implicated as a potential mediator of macrophage migration inhibition (72) , and C5a also exerts profound effects on neutrophils (73) .
Complement has been considered a mediator of humoral immunity, active in antibody-mediated lysis of bacteria and cells, and in anaphylactic and Arthus reactions. The recognition that lymphocytes and monocytes synthesize and activate complement, and that factor Bb induces significant changes in the physiology of mononuclear phagocytes, raises the possibility that proteins of the leukocyte complement system may also serve as mediators of cellular immunity.
Summary
The central serine esterase of the alternative pathway of complement (APC) activation, activated factor B (Bb), has been shown recently to induce murine macrophages and human monocytes to become spread on a glass substrata. It has also been established that to induce the spreading reaction, the catalytic site of the Bb enzyme must be structurally intact since treatment of Bb with heat (56°C for 30 min) or diisopropylfluorophosphate (10 -3 M) destroyed both enzymatic and spreading activities. In the C3b,Bb complex, Bb exhibits restricted substrate specificity for C3 and C5. With this in mind, the role of C3 and C5 in the monocyte spreading reaction was explored in the present study. Expression of C3 and C5 on the surface of human peripheral blood monocytes was investigated by the direct fluorescent antibody technique employing fluorescein isothiocyanate-conjugated anti-C3 or C5 F(ab')2 antibody fragments. It was found that C3 and C5 were present on 6 + 7% of freshly prepared monocytes and that expression of C5, but not C3, increased to 70 _ 6% when monocytes were incubated for 3 d in serum-free medium. Biosynthesis of C5 was indicated when it was found that under serum-free conditions, monocytes incorporated [3H]leucine into immunoprecipitable C5 with an apparent mol wt of 180,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The role of C3 and C5 in the monocyte spreading reaction induced by factor Bb was explored by testing for the ability of anti-C3 and anti-C5 Fab' antibody fragments to block monocyte spreading. It was found that anti-C5 Fab' inhibited by up to 100% the 3-h human monocyte spreading reaction induced by Bb; in contrast, anti-C3 Fab' or anti-C4 Fab' inhibited by <10%. That the inhibitory effect of anti-C5 Fab' was exerted directly on the monocyte was established when it was found that the 3-h monocyte spreading reaction was significantly inhibited by pretreating monocytes with anti-C5 Fab' for 20 min and then washing before the addition of Bb. The specificity of the inhibitory effect of anti-C5 Fab' was established by quantitatively absorbing the antibody fragments with polyacrylamide gel-purified C5 antigen: >4 /~g of C5 absorbed by 100% the inhibitory activity of 10-20/~g of anti-C5 Fab'. That factor Bb exerted its effect on monocytes by interacting directly with cell surface C5 was indicated when it was found that purified C5 inhibited the monocyte spreading reaction induced by Bb; :>25 #g of C5 inhibited by 100% the spreading reaction induced by 3 #g factor Bb.
